For patients with advanced or inoperable cancers, minimally invasive therapies have become one of the preferred treatment options. Local ablation methods such as cryoablation, NanoKnife ablation, microwave ablation, and radioactive iodine seed implantation have shown promising clinical results. The development of immune checkpoint blockade therapies and chimeric antigen receptor T-cell (CAR-T) therapies has greatly advanced the clinical application of immunotherapy in treating malignant tumors. In recent years, studies have shown that combining immunotherapy with minimally invasive or traditional treatments can significantly prolong overall survival. For example, immune checkpoint inhibitors—such as anti-PD-1 antibodies—have demonstrated strong synergistic effects when used alongside minimally invasive therapies in many types of cancer, effectively improving patient outcomes. This approach has become a distinctive feature of our hospital’s treatment strategy, offering new hope and substantial benefits to an increasing number of patients.

Integration of Local and Systemic Therapies: Local treatments such as cryoablation, radiofrequency ablation, radiotherapy, and surgery can eliminate or reduce tumor burden, creating favorable conditions for systemic therapies. Cryoablation, in particular, has a “cryo-immunological” effect that stimulates immune activation. When combined with systemic immunotherapy, this local–systemic synergy can significantly enhance overall treatment efficacy.

Combination of Distinct Antitumor Mechanisms: Different immunotherapies function through various mechanisms to activate or regulate the immune system. By combining or sequencing therapies with complementary mechanisms, the overall immune response can be strengthened, offering a more comprehensive and effective antitumor effect.

Indications for Combined Immunotherapy

1. Patients who have undergone surgical resection of solid tumors

2. Patients with progressive tumors that are unresectable or unsuitable for surgery due to other medical conditions

3. Patients with recurrent tumors

4. Certain benign tumors that require treatment but cannot be addressed surgically